7R7R
Structure of Human Anaplastic Lymphoma Kinase Domain in complex with ((2~{R})-2-[5-[6-amino-5-[(1~{R})-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]-3-pyridyl]-4-methyl-thiazol-2-yl]propane-1,2-diol)
Summary for 7R7R
Entry DOI | 10.2210/pdb7r7r/pdb |
Descriptor | ALK tyrosine kinase receptor, (2R)-2-[5-(6-amino-5-{(1R)-1-[2-(1,3-dihydro-2H-1,2,3-triazol-2-yl)-5-fluorophenyl]ethoxy}pyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol (3 entities in total) |
Functional Keywords | kinase, transferase |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 1 |
Total formula weight | 37381.89 |
Authors | McTigue, M. (deposition date: 2021-06-25, release date: 2022-06-29, Last modification date: 2023-10-18) |
Primary citation | Shiba-Ishii, A.,Johnson, T.W.,Dagogo-Jack, I.,Mino-Kenudson, M.,Johnson, T.R.,Wei, P.,Weinrich, S.L.,McTigue, M.A.,Walcott, M.A.,Nguyen-Phuong, L.,Dionne, K.,Acker, A.,Kiedrowski, L.A.,Do, A.,Peterson, J.L.,Barth, J.L.,Yeap, B.Y.,Gainor, J.F.,Lin, J.J.,Yoda, S.,Hata, A.N. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat Cancer, 3:710-722, 2022 Cited by PubMed: 35726063DOI: 10.1038/s43018-022-00399-6 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.935 Å) |
Structure validation
Download full validation report